Skip to main content

Table 3 The comparison of prevalence of 8 comorbidities between included COVID-19 patients and the Chinese population [48,49,50,51,52,53]

From: Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors

Disease Prevalence from Meta-analysis (%) Prevalence from the general population (%) P-value *** Reference a
Hypertension 19 23.2 < 0.001 2018 [48]
Cardiovascular disease 6 1.8 < 0.001 2018 [48]
Cerebrovascular disease 2 0.9 < 0.001 2018 [48]
Diabetes 9 10.9 < 0.001 2013 [50]
COPD 3 8.6 < 0.001 2018 [51]
Chronic liver disease 3 > 24.8 < 0.001 2019 [52]
Chronic kidney disease 2 9.5 < 0.001 2017 [53]
Malignancy 1 0.6 < 0.001 Recent 5-year [49]
  1. *** P < 0.001 The significant difference between the two groups is indicated by the u-test
  2. aaReferences for the incidence of the indicated diseases in the general population were included in parenthesis. Dates under the heading of Reference refer to the year in which statistic data was collected before